Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
8%
Ph phase_4
9
75%
Ph phase_2
1
8%

Phase Distribution

0

Early Stage

1

Mid Stage

10

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
9(81.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(5)
Other(7)

Detailed Status

unknown7
Completed5

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (9.1%)
Phase 31 (9.1%)
Phase 49 (81.8%)

Trials by Status

unknown758%
completed542%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_2

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.

NCT05463419
unknownphase_4

Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

NCT05329038
completedphase_3

Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents

NCT04992260
completedphase_4

Immunogenicity of an Inactivated COVID-19 Vaccine

NCT05198336
completed

Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic

NCT04974164
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05463419Phase 2

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.

Completed
NCT05329038Phase 4

Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

Unknown
NCT04992260Phase 3

Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents

Completed
NCT05198336Phase 4

Immunogenicity of an Inactivated COVID-19 Vaccine

Completed
NCT04974164

Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic

Completed
NCT04953325Phase 4

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

Completed
NCT05105295Phase 4

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected

Unknown
NCT05104216Phase 4

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD

Unknown
NCT05075070Phase 4

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected

Unknown
NCT05075057Phase 4

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD

Unknown
NCT05075083Phase 4

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD

Unknown
NCT05075044Phase 4

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected

Unknown

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12